Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Gaush Meditech Ltd. ( (HK:2407) ) is now available.
Gaush Meditech Ltd has renewed its exclusive distribution agreement with Germany-based Schwind eye-tech-solutions GmbH, a leading supplier of refractive surgery devices. This renewal strengthens their long-term partnership, enhancing Gaush Meditech’s competitive advantage in China’s refractive surgery device market and potentially boosting performance growth.
The most recent analyst rating on (HK:2407) stock is a Buy with a HK$10.50 price target. To see the full list of analyst forecasts on Gaush Meditech Ltd. stock, see the HK:2407 Stock Forecast page.
More about Gaush Meditech Ltd.
Gaush Meditech Ltd is a company incorporated in the Cayman Islands, operating in the medical technology industry. It focuses on the distribution and promotion of refractive surgery devices, particularly in the Chinese market, including Mainland China, Hong Kong, and Macau. The company collaborates with international partners to provide advanced ophthalmic solutions.
Average Trading Volume: 161,216
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.36B
Learn more about 2407 stock on TipRanks’ Stock Analysis page.